Maternal circulatory levels of procalcitonin, uric acid, and lipid profile in Early-onset preeclampsia and Late-onset preeclampsia

Ravoori Saideswar  Rao; Manisha Singh; Ritu Sharma; Mamta Padhy; Preeti Sharma; Rakesh Gupta

doi:10.53730/ijhs.v6nS5.8913

Authors

Ravoori Saideswar Rao Tutor, Department of Biochemistry, Government Institute of Medical Sciences, Greater Noida, UP, India
Manisha Singh
manishakamendu@gmail.com
Associate Professor, Department of Biochemistry, Government Institute of Medical Sciences, Greater Noida, UP, India
Ritu Sharma Associate Professor, Department of Obstetrics and Gynecology, Government Institute of Medical Sciences, Greater Noida, UP, India
Mamta Padhy Assistant Professor, Department of Biochemistry, Government Institute of Medical Sciences, Greater Noida, UP, India
Preeti Sharma Professor, Department of Biochemistry, Santosh Medical College & Hospital, Ghaziabad, UP, India
Rakesh Gupta Department of Pediatrics, Government Institute of Medical Sciences, Greater Noida, UP, India

Keywords:

Preeclampsia, procalcitonin, uric acid, lipid profile

Abstract

Aim: To determine the circulatory procalcitonin levels, lipid profile and uric acid levels in patients presenting with preeclampsia and to correlate these with clinical severity of the disease. Methodology: This double blinded case-control study was conducted for two years in department of Obstetrics and Gynecology in collaboration with the department of biochemistry, Government Institute of Medical Sciences, Greater Noida, UP. This study included 80 subjects out of 40 were in group I (Control) and other 40 were in group II (PE patients) admitted in the hospital in third trimester of pregnancy. General demographic and clinical data such as age, gestational week, number of gestation, and BMI were recorded, and the results of routine blood cell counts, PCT and other indicators were also obtained. The PE patients were women younger than 40 years old who met the diagnostic criteria for PE in the guidelines for diagnosis and treatment of hypertensive diseases in pregnancy-2014. The healthy pregnant women were between 24 and 40 years old, with a single fetus, normal fetal development, normal liver and kidney function, and without eclampsia, gestational diabetes mellitus, fetal growth restriction, or history of other adverse pregnancy conditions.

Downloads

Download data is not yet available.

References

Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol. 2012 Feb;36(1):56-9.

Berhan Y, Endeshaw G. Maternal mortality predictors in women with hypertensive disorders of pregnancy: a retrospective cohort study. Ethiop J Health Sci. 2015 Jan;25(1):89-98.

Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009 Jun;33(3):130-7.

WHO Recommendations for Prevention and Treatment of Preeclampsia and Eclampsia, WHO Department of Maternal and Child Health, Geneva, Switzerland, 2011.

Steinberg G, Khankin EV, Karumanchi SA. “Angiogenic factors and preeclampsia,” Thrombosis Research. 2009;123: S93–S99.

Ramma W, Ahmed A.“Is inflammation the cause of pre-eclampsia?” Biochemical Society Transactions. 2011; 39(6):1619-27.

Clifton VL, Stark MJ, Osei-Kumah A, Hodyl NA, “Review: the feto-placental unit, pregnancy pathology and impact on long term maternal health,” Placenta. 2012;33:S37–S41.

Moya F, Nieto A, R-candela JL. Calcitonin biosynthesis: evidence for a precursor. Eur J Biochem 1975; 55:407-13.

Allison J, Hall L, MacIntyre I, Craig RK. The construction and partial characterization of plasmids containing complementary DNA sequences to human calcitonin precursor polyprotein. Biochem J 1981; 199:725–31.

Vijayan AL, Ravindran S, Saikant R, Lakshmi S, Kartik R. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. J Intens Care 2017; 5:51.

Rhee C. Using procalcitonin to guide antibiotic therapy. Open Forum Infect Dis 2017; 4:ofw249.

Artunc-Ulkumen B, Guvenc Y, Goker A, Gozukara C. Relationship of neutrophil gelatinase-associated lipocalin (NGAL) and procalcitonin levels with the presence and severity of the preeclampsia. J Matern Fetal Neonatal Med 2015; 28:1895–900.

Kucukgoz Gulec U, Tuncay Ozgunen F, Baris Guzel A, Buyukkurt S, Seydaoglu G, Ferhat Urunsak I, Cuneyt Evruke I. An analysis of C-reactive protein, procalcitonin, and D-dimer in pre-eclamptic patients. Am J Reprod Immunol. 2012 Oct;68(4):331-7.

Can M, Sancar E, Harma M, Guven B, Mungan G, Acikgoz S. Inflammatory markers in preeclamptic patients. Clin Chem Lab Med 2011; 49:1469-72.

Many A, Hubel CA, Roberts JM. Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Am J Obstet Gynecol. 1996;174(1):288-291.

Cheung KL, Lafayette RA. Renal physiology of pregnancy. Adv Chronic Kidney Dis. 2013;20(3):209-214.

Khaliq OP, Konoshita T, Moodley J, Naicker T. The role of uric acid in preeclampsia: is uric acid a causative factor or a sign of preeclampsia? CurrHypertens Rep. 2018;20(9):80.

Martin AC, Brown MA. Could uric acid have a pathogenic role in pre-eclampsia? Nat Rev Nephrol. 2010;6(12):744-748.

Bainbridge SA, Roberts JM. Uric acid as a pathogenic factor in preeclampsia. Placenta. 2008;29:67-72.

Rambaldi MP, Weiner E, Mecacci F, Bar J, Petraglia F. Immunomodulation and preeclampsia. Best Pract Res Clin Obstet Gynaecol. 2019 Oct;60:87-96.

Klainbart S, Slon A, Kelmer E, Bdolah-Abram T, Raz T, Segev G, Aroch I, Tal S. Global hemostasis in healthy bitches during pregnancy and at different estrous cycle stages: Evaluation of routine hemostatic tests and thromboelastometry. Theriogenology. 2017 Jul 15;97:57-66.

Rodriguez A, Tuuli MG, Odibo AO. First-, Second-, and Third-Trimester Screening for Preeclampsia and Intrauterine Growth Restriction. Clin Lab Med. 2016 Jun;36(2):331-51.

Na XN, Xia YJ. Thromboelastic diagram and clotting evaluation of low molecular weight heparin in improving clotting function in patients with severe preeclampsia. J ObstetGynecol 2019;35:146-9

Figueroa SA, Merriman-Noesges K. Utility of thromboelastography in traumatic brain injury and the neuroscience intensive care unit. J NeurosciNurs 2014;46:66-70.

Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 2002; 323:17-29.

Vijayan AL, Ravindran S, Saikant R, Lakshmi S, Kartik R. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. J Intens Care 2017; 5:51.

Matwiyoff GN, Prahl JD, Miller RJ et al. Immune regulation of procalcitonin: a biomarker and mediator of infection. Inflamm Res 2012; 61:401–9.

Wagner NM, Van Aken C, Butschkau A et al. Procalcitonin impairs endothelial cell function and viability. AnesthAnalg 2017; 124:836–45.

Sauer M, Doss S, Ehler J, Mencke T, Wagner NM. Procalcitonin impairs liver cell viability and function in vitro: a potential new mechanism of liver dysfunction and failure during sepsis? Biomed Res Int 2017; 2017:6130725

Milne F, Redman C, Walker J et al. Assessing the onset of pre-eclampsia in the hospital day unit: summary of the preeclampsia guideline (PRECOG II). BMJ 2009; 339:b3129.

Agostinis C, Rami D, Zacchi P et al. Pre-eclampsia affects procalcitonin production in placental tissue. Am J ReprodImmunol 2018; 79:e12823.

Hu Y, Yang M, Zhou Y, Ding Y, Xiang Z, Yu L. Establishment of reference intervals for procalcitonin in healthy pregnant women of Chinese population. ClinBiochem 2017; 50:150-4.

Bellomo G. Serum uric acid and preeclampsia: An update. Expert Rev Cardiovasc Ther. 2012;10:701-5.

Zhou J, Zhao X, Wang Z, Hu Y. Combination of lipids and uric acid in mid-trimester can be used to predict adverse pregnancy outcomes. J Matern Fetal Neonatal Med. 2012;25:2633-8.

Hawkins TL, Roberts JM, Mangos GJ, Davis GK, Roberts LM, Brown MA. Plasma uric acid remains a marker of poor outcome in hypertensive pregnancy: A retrospective cohort study. BJOG. 2012;119:484-92.